
Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Septerna, Inc. (SEPN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37,33, with a market capitalization of $1,72B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13,67 to $51,10. This page covers its latest market performance, valuation, price trends and company information.
$1,72B | |
$36,15 | |
$51,10 | |
$4,17 | |
$36,75 | |
262,74K | |
440,27K | |
-- | |
$51,10 | |
$13,67 | |
-- | |
-- |
Septerna, Inc. (SEPN) last closed at $36,75 as of 2026-09-08 23:31:00, unchanged from the previous close of $36,75.
During the latest regular trading session, SEPN traded between $4,17 and $51,10, with a volume of 262,74K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Septerna, Inc. (SEPN) moved from $40,47 to $37,33, representing a decline of 7,77% ($3,14).
The stock traded between $35,93 and $41,08 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 290,89 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63,2%
SEPN is currently trading at $37,33, placing it 63,2% of the way from its 52-week low of $13,67 to its 52-week high of $51,10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Septerna, Inc. (SEPN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.